Cargando…
A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?
Measures of the severity of cognitive impairment or parkinsonism are the usual endpoints in clinical trials for Alzheimer’s disease (AD) and Parkinson’s disease (PD), but are critically hampered by their lack of disease sensitivity and specificity. Due to the high failure rate of clinical trials, th...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520818/ https://www.ncbi.nlm.nih.gov/pubmed/28733961 http://dx.doi.org/10.1007/s40120-017-0072-x |